(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently ... The medication, to be sold under the name Cobenfy, was a key piece ...

The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older therapies, writes Julie Coleman for CNBC..Bristol ...

The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics. Cerevel Therapeutics drug tavapadon met the main and ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used ... Get local news you need to know to start your day with NBC 6's News Headlines newsletter.